Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine if the combination of cetuximab, carboplatin and
paclitaxel will shrink a specific type of lung cancer known as non-small cell lung cancer
(NSCLC). The safety of this combination will also be evaluated.